AKR1C3 and prostate carcinoma: Specific inhibitors of AKR1C1 (3-bromo-5-phenylsalicylic acid) and AKR1C3 (tolfenamic acid, indomethacin; phase I/II trial in prostate cancer, NCT02935205)) are also available.